Brightsurf Science News & Current Events

February 27, 2016
Eylea outperforms Avastin for diabetic macular edema with moderate or worse vision loss
A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea than for those receiving Avastin, but only among participants starting treatment with 20/50 or worse vision. is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to